Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris

Shares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon Biologics Ltd. Biocon is a privately held biopharma company based in India.

Viatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus

Sanofi SA (NASDAQ: SNY) has raised its 2021 profit forecast after its vaccines and blockbuster eczema treatment Dupixent helped boost second-quarter results. Q2 2021 sales grew 6.55 Y/Y to €8.7 billion (up 12.4% at CER), mainly driven by Dupixent and new oncology.

Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast

Regeneron Pharmaceuticals

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease. The 138-subject study met its primary endpoints and all key secondary endpoints at 24 weeks.

Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients

Sanofi raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday.

Sanofi raises profit forecasts after strong second quarter

Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's (NASDAQ: SNY) avalglucosidase alfa for Pompe disease. The positive opinion is based on Phase 3 COMET study data, which showed avalglucosidase alfa improved respiratory function and movement endurance measures.

Sanofi's Pompe Disease Enzyme Replacement Therapy Gets EMA's CHMP Backing

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all patients, and the data is pointing them towards former smokers. What Happened: A phase 2a study, published in The Lancet, showed that the companies' itepekimab, a monoclonal antibody lowered acute COPD exacerbations in former smokers.

Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers

Ashtead Group PLC

British American Tobacco

Diageo

EssilorLuxottica SA

Fresenius Medical Care

L'Oreal SA

Nestle SA

Novartis

Roche Holding AG

Unilever

Wolters Kluwer NV

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your Portfolio appeared first on InvestorPlace.

15 European Dividend Aristocrats to Diversify Your Portfolio

GlaxoSmithKline

EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NASDAQ: GSK), which started a 35,000-patient Phase 3 trial in May. The vaccine dubbed Vidprevtyn is based on a recombinant protein antigen developed by Sanofi and includes an immune-boosting adjuvant developed by GSK to boost its efficacy.

EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine

The FDA has approved Sanofi SA's (NASDAQ: SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness in patients six years of age and older and weighing at least 20 kg. Sleeping sickness is a parasitic disease transmitted by the bite of an infected tse-tse fly.

Sanofi's Oral Treatment For Sleeping Sickness Gets FDA Approval

Danone SA

LVMH Moet Hennessy Louis Vuitton

Orange

Bastille Day is France's National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept of revolution was a tad more boisterous than the American version — the Marquis de Launay, the governor of the Bastille, was decapitated by a butcher and his head was paraded through Paris on a spike — today's Bastille Day offers a colorful celebration of the noble concepts of liberty, equality and fraternity.

5 French Stocks To Consider For Bastille Day

Press release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)

Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Sanofi (SNY) Stock Undervalued Right Now?

Eli Lilly

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate. The companies in May started global trials to include more than 35,000 adults to test the candidate and hope to get approvals by the end of 2021.

Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India

The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients severely or critically ill with COVID-19 often suffer from an overreaction of the immune system.

WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients

The World Health Organization began recommending the use of medicines called interleukin-6 receptor blockers as COVID-19 treatments for the severely ill, based on the findings of a large clinical study published Tuesday in JAMA. Roche Holding AG's Actemra and Sanofi and Regeneron Pharmaceuticals Inc.'s Kevzara are both approved in the U.S. as treatments for rheumatoid arthritis.

WHO recommends Roche, Sanofi/Regeneron drugs as COVID-19 treatments, calls for lower prices

French pharmaceutical giant Sanofi SA (LON:0O59) said Monday its Covid-19 vaccine developed in partnership with UK Pharma GlaxoSmithKline Plc (NYSE:GSK) could be ready for roll-out by December. Sanofi is one of the few global vaccine developers yet to roll out a Covid-19 vaccine, but things could change before the year ends.

As Sanofi launches its Covid vaccine by December, should you invest now?

AbbVie

Cardinal Health

Chevron

Imperial Brands PLC

Realty Income Corp

Red Electrica Corp SA

Swiss Re AG

AT&T

Exxon Mobil

Kiplinger "insights for investors" online, first listed 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth as of 7/1/21. 39 European “Dividend Aristocrats,” show 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats show 25 years of increases for U.S. companies.

102 'Top Dividend Stocks On Earth' July Update

Walmart

Novo Nordisk

The discount chain's private label sells at prices more than 50% lower than brand names made by Lilly, Sanofi, and Novo Nordisk.

Now on Sale at Walmart: Insulin That's Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk

Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology.

Sanofi Invests To Build Internal Capabilities in mRNA

The vaccine heavyweight will invest nearly $480 million a year to develop mRNA vaccines for other diseases.

Sanofi Is Injecting Almost Half A Billion Dollars Each Year Into mRNA Tech Driving Pfizer, Moderna Covid Shots

Sanofi launches dedicated v accines mRNA Center of Excellence

Sanofi launches dedicated vaccines mRNA Center of Excellence

Amid a reorganization scheme aimed at slashing costs and prioritizing blockbuster immunology Dupixent, Sanofi SA (NASDAQ: SNY) will offload 16 consumer health products to Germany's Stada Arzneimittel.  Under the deal, which is expected to close in the third quarter, Stada will get its hands on the registrations, trademarks, and commercial rights for the products across 13 countries.

News for Sanofi Stock (SNY)